Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
Completed · Phase 1
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Vaccines made from gp100 and sargramostim may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy with gp100 and/or sargramostim in treating patients who have malignant melanoma.
Key facts
- Study ID
- NCT00003897
- Run by
- University of Wisconsin, Madison
- People needed
- 18
- Starts
- 1999-05-01
- Expected to finish
- 2006-12-01
- Last updated by the study team
- 2019-11-19
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.